Literature DB >> 20223693

Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection.

Cristina Suárez1, Carmen Peña, Laura Gavaldà, Fe Tubau, Adriana Manzur, M Angeles Dominguez, Miquel Pujol, Francesc Gudiol, Javier Ariza.   

Abstract

OBJECTIVE: We aimed to study the influence of carbapenem resistance on attributable mortality in a cohort of patients with Pseudomonas aeruginosa bacteremia.
METHODS: Data on 121 episodes of P. aeruginosa bacteremia occurring between January and December 2005 were retrospectively analyzed.
RESULTS: Thirty-three episodes were caused by carbapenem-resistant P. aeruginosa (CRPA) strains and 88 by carbapenem-susceptible P. aeruginosa (CSPA) strains. There was no significant difference in mortality between the groups (33% in CRPA vs. 30% in CSPA; p = 0.69). However, a Kaplan-Meier survival analysis showed that in the first 48h after the onset of bacteremia, there was a lower cumulative mortality proportion in the CRPA group than in the CSPA group (13% vs. 50%; p = 0.026). The independent risk factors associated with death in P. aeruginosa bacteremia were clinical presentation with severe sepsis (odds ratio (OR) 38, 95% confidence interval (CI) 10.2-142.2) and bacteremia of high-risk origin (OR 6.6, 95% CI 1.6-26.9).
CONCLUSIONS: According to our data, carbapenem resistance was not associated with higher mortality in patients with P. aeruginosa bacteremia. The slower initial mortality in the CRPA group might have implications in the design of the optimal antibiotic policy strategy.
Copyright © 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20223693     DOI: 10.1016/j.ijid.2009.11.019

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  17 in total

1.  Infections caused by multidrug resistant organisms are not associated with overall, all-cause mortality in the surgical intensive care unit: the 20,000 foot view.

Authors:  Laura H Rosenberger; Damien J LaPar; Robert G Sawyer
Journal:  J Am Coll Surg       Date:  2012-03-13       Impact factor: 6.113

2.  Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure.

Authors:  Deanna J Buehrle; Ryan K Shields; Lloyd G Clarke; Brian A Potoski; Cornelius J Clancy; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

3.  Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections.

Authors:  Carmen Peña; Cristina Suarez; Mónica Gozalo; Javier Murillas; Benito Almirante; Virginia Pomar; Manuela Aguilar; Ana Granados; Esther Calbo; Jesús Rodríguez-Baño; Fernando Rodríguez; Fe Tubau; Luis Martínez-Martínez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

Review 4.  A systematic review and meta-analyses show that carbapenem use and medical devices are the leading risk factors for carbapenem-resistant Pseudomonas aeruginosa.

Authors:  Anne F Voor In 't Holt; Juliëtte A Severin; Emmanuel M E H Lesaffre; Margreet C Vos
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

5.  Pathogenic characteristics of Pseudomonas aeruginosa bacteraemia isolates in a high-endemicity setting for ST175 and ST235 high-risk clones.

Authors:  Raúl Recio; Irina Sánchez-Diener; Esther Viedma; María Ángeles Meléndez-Carmona; Jennifer Villa; María Ángeles Orellana; Mikel Mancheño; Carlos Juan; Laura Zamorano; Jaime Lora-Tamayo; Fernando Chaves; Antonio Oliver
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-12-10       Impact factor: 3.267

6.  Influence of carbapenem resistance on mortality of patients with Pseudomonas aeruginosa infection: a meta-analysis.

Authors:  Qianqian Liu; Xiaoqing Li; Wenzhang Li; Xinmiao Du; Jian-Qing He; Chuanmin Tao; Yulin Feng
Journal:  Sci Rep       Date:  2015-06-25       Impact factor: 4.379

7.  Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy.

Authors:  Youn Jeong Kim; Yoon Hee Jun; Yang Ree Kim; Kang Gyun Park; Yeon Joon Park; Ji Young Kang; Sang Il Kim
Journal:  BMC Infect Dis       Date:  2014-03-24       Impact factor: 3.090

8.  Estimating the morbidity and mortality associated with infections due to multidrug-resistant bacteria (MDRB), France, 2012.

Authors:  M Colomb-Cotinat; J Lacoste; C Brun-Buisson; V Jarlier; B Coignard; S Vaux
Journal:  Antimicrob Resist Infect Control       Date:  2016-12-12       Impact factor: 4.887

9.  Pseudomonas Aeruginosa Bacteraemia in Two UK District Hospitals.

Authors:  David A Enoch; Julie Kuzhively; Andrew Sismey; Alina Grynik; Johannis Andreas Karas
Journal:  Infect Dis Rep       Date:  2013-09-11

Review 10.  Mortality attributable to carbapenem-resistant Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies.

Authors:  Yu Zhang; Xiao-Li Chen; Ai-Wei Huang; Su-Ling Liu; Wei-Jiang Liu; Ni Zhang; Xu-Zai Lu
Journal:  Emerg Microbes Infect       Date:  2016-03-23       Impact factor: 7.163

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.